Previous Close | 3.6000 |
Open | 3.6000 |
Bid | 4.6000 |
Ask | 5.2000 |
Strike | 11.00 |
Expire Date | 2024-10-18 |
Day's Range | 3.6000 - 3.6100 |
Contract Range | N/A |
Volume | |
Open Interest | 260 |
With the business potentially at an important milestone, we thought we'd take a closer look at Ardelyx, Inc.'s...
WALTHAM, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that on May 23, 2024, the compensation committee of the company’s board of directors granted 10 new non-executive employees options to purchase an aggregate of 210,000 shares of the company’s common stock, and granted 13 new non-execut
WALTHAM, Mass., May 22, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that Michael Raab, President and CEO, and Justin Renz, chief financial and operations officer, will participate in a fireside chat at the 2024 Jefferies Global Healthcare Conference on Wednesday, June 5, 2024 at 10:00 A.M. Eastern Time